- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05903690
Safety and Tolerability of RAG-17 in the Treatment of Amyotrophic Lateral Sclerosis Patients With SOD1 Gene Mutation
June 11, 2023 updated by: yilong Wang, Beijing Tiantan Hospital
The goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics of RAG-17 in adult amyotrophic lateral sclerosis (ALS) patients with SOD1 mutation.
Patients will receive drug treamtent via dose escalation which ranging from minimum of 60 mg to the maximum tolerated dose (MTD), after reaching the tolerated dose, a fixed dose of the drug is given once every two months for continuous treatment, and the total treatment cycle is 8 months.
The duration of this study is two years.
Study Overview
Detailed Description
This study is an open-label, single center, first-in-Human dose escalation study to evaluate the safety, tolerability and pharmacokinetics of RAG-17 in adultamyotrophic lateral sclerosis (ALS) patients with SOD1 mutation via dose escalations.
Patients will receive 60mg of RAG-17 firstly, within 14 days after the first administration, the subject has no adverse event (AE) and serious adverse event (SAE), the subject can accept dose escalation every 30mg/14 days of observation period.
3 to 4 dose escalations are planned to reach the dose limiting toxicity (DLT), with optimal doses for continual 6-month treatment cycles.
For the dose of subsequent continuous treatment, an optimal dose between the safe dose and the maximum tolerated dose (MTD) is selected as the continuous treatment dose.
SAS software is used for safety analysis.
The sample size of this study is 6 ALS patients with SOD1 mutation.
Study Type
Interventional
Enrollment (Estimated)
6
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China, 100050
- Beijing Tiantan Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients who are judged by professional medical staff to still be able to carry out the clinical trial project cycle;
- 18 years old ≤ age ≤ 75 years old, males or females;
- ALS patients with confirmed SOD1 gene mutations document (known SOD1 mutation sites and related disease progression have been reported);
- Forced vital capacity ≥ 80% of predicted vital capacity during the screening period;
- Diagnosis of confirmed or probable familial or sporadic ALS in accordance with the revised EI Escorial diagnostic criteria for amyotrophic lateral sclerosis of the World Federation of Neurology;
- The patient or patient's legal representative clearly understands and voluntarily participates in the study and signs the informed consent form;
- Subjects (including male subjects) are willing to have no birth plan and voluntarily take effective contraceptive measures during the entire study period and within 3 months after the end of the study, and have no plan to donate sperm or eggs.
Exclusion Criteria:
- Patients with SOD1 mutations occurring at nucleotides 44 to 66 (calculated from the start of SOD1 protein translation), patients with P.F21C mutation;
- Patients who have previously received or are currently receiving Tofersen treatment;
- HIV test positive or history of positive tests;
- Positive hepatitis C virus antibody or history of positive tests;
- Active hepatitis B infection (positive hepatitis B surface antigen and/or positive hepatitis B core antibody);
- Have used other investigational drugs within 1 month or within 5 drug half-lives;
- Diseases and deformities of the lumbar spine;
- Have other conditions known to be associated with motor neuron dysfunction that may confuse or obscure an ALS diagnosis;
- Other psychiatric disorders diagnosed according to DSM-V diagnostic criteria, or significant suicide intent;
- With severe hepatic insufficiency, renal insufficiency or severe cardiac insufficiency (severe hepatic insufficiency refers to ALT value≥2.0 times the upper limit of normal value or AST value≥2.0 times the upper limit of normal value; severe renal insufficiency refers to CRE≥1.5 times the upper limit of normal value or eGFR<40mL/min/1.73m2; severe cardiac insufficiency refers to NYHA class 3-4);
- Permanently dependent on ventilator-assisted ventilation;
- History of alcohol and drug abuse;
- Patients who are pregnant, breast-feeding, or who are likely to become pregnant and plan to become pregnant;
- Patients participating in other clinical trials or using other biological agents, drugs or devices under investigation;
- Patients who have received any vaccinations within 28 days;
- Contraindications to MRI (eg, claustrophobia);
- Unable to be cooperative and complete the follow-up due to other reasons.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RAG-17
Doses of RAG-17 will range from a minimum of 60 mg to the maximum tolerated dose (MTD).
Dosing once every two weeks, starting from 60 mg, with dose escalation.
After reaching the tolerated dose, a fixed dose of the drug is given once every two months for continuous treatment, and the total treatment cycle is 8 months.
|
RAG-17 60mg is used
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events (AE) and serious adverse events (SAE)
Time Frame: Within 180 days after treatment
|
The incidence of adverse events (AE) and serious adverse events (SAE) within 180 days after RAG-17 treatment, and number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) V5.0
|
Within 180 days after treatment
|
Clinical laboratory examination index
Time Frame: Before RAG-17 treatment and within 180 days after treatment
|
Monitor the abnormal change of clinical laboratory Index generated from general examination results before RAG-17 treatment, and within 180days after RAG-17 treatment, which including blood testing and urine testing.
Eventually to determine the safety and tolerability of RAG-17 on adult ALS patients.
|
Before RAG-17 treatment and within 180 days after treatment
|
Physiological Parameter-Vital Sign: Body Temperature
Time Frame: Within 180 days after treatment
|
Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients.
Vital sign that is measured including body temperature in degree Celsius.
|
Within 180 days after treatment
|
Physiological Parameter-Vital Sign: Pulse Rate
Time Frame: Within 180 days after treatment
|
Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients.
Vital sign that is measured including pulse rate in beats per minute.
|
Within 180 days after treatment
|
Physiological Parameter-Vital Sign: Respiration Rate
Time Frame: Within 180 days after treatment
|
Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients.
Vital sign that is measured including respiration rate in breaths per minute.
|
Within 180 days after treatment
|
Physiological Parameter-Vital Sign: Blood Pressure
Time Frame: Within 180 days after treatment
|
Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients.
Vital sign that is measured including blood pressure in mmHg.
|
Within 180 days after treatment
|
Physiological Parameter-Vital Signs: Height, Hip Circumference and Waist
Time Frame: Within 180 days after treatment
|
Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients.
Vital signs that are measured including height, hip circumference and waist in centimeter.
|
Within 180 days after treatment
|
Physiological Parameter-Vital Signs: Weight
Time Frame: Within 180 days after treatment
|
Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients.
Vital sign that is measured including body weight in kilogram.
|
Within 180 days after treatment
|
Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R)
Time Frame: Within 180 days after treatment
|
Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) is a questionnaire-based scale that is used to measure the change in functional impairment of adult ALS patients within 180 days after RAG-17 treatment.
ALSFRS-R scale measures 12 aspects of physical function, and each function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0.
|
Within 180 days after treatment
|
Neurological examinations
Time Frame: Within 180 days after treatment
|
Incidence rate of abnormalities in neurological examinations within 180 days after RAG-17 treatment
|
Within 180 days after treatment
|
Heart circulatory system examinations
Time Frame: Within 180 days after treatment
|
Incidence rate of abnormalities in heart circulatory system examinations within 180 days after RAG-17 treatment
|
Within 180 days after treatment
|
Respiratory system examinations
Time Frame: Within 180 days after treatment
|
Incidence rate of abnormalities in respiratory system examinations within 180 days after RAG-17 treatment
|
Within 180 days after treatment
|
Abdominal examinations
Time Frame: Within 180 days after treatment
|
Incidence rate of abnormalities in abdominal examinations within 180 days after RAG-17 treatment
|
Within 180 days after treatment
|
ECG results
Time Frame: Within 180 days after treatment
|
Incidence rate of abnormalities in ECG results within 180 days after RAG-17 treatment
|
Within 180 days after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SOD1 protein levels
Time Frame: day 1, day 15, day 29, day 60, day 120, day 180 and day 240
|
Changes of SOD1 protein levels in cerebrospinal fluid from baseline on day 1, day 15, day 29, day 60, day 120, day 180 and day 240 of adult ALS patients after RAG-17 treatment
|
day 1, day 15, day 29, day 60, day 120, day 180 and day 240
|
Plasma neurofilament light (NFL) levels
Time Frame: day 1, day 15, day 29, day 60, day 120, day 180 and day 240
|
Changes in plasma neurofilament light (NFL) levels from baseline on day 1, day 15, day 29, day 60, day 120, day 180 and day 240 in adult ALS patients after RAG-17 treatment
|
day 1, day 15, day 29, day 60, day 120, day 180 and day 240
|
Pharmacokinetic Changes of RAG-17
Time Frame: day 1, day 15, day 29, day 60, day 120, day 180 and day 240
|
Pharmacokinetic Parameter changes of RAG-17 in Plasma: Maximum Observed Concentration (Cmax) on day1, day15, day29, day60, day120, day180 and day240 in adult ALS patients after RAG-17 treatment
|
day 1, day 15, day 29, day 60, day 120, day 180 and day 240
|
Pharmacokinetic Changes of RAG-17
Time Frame: day 1, day 15, day 29, day 60, day 120, day 180 and day 240
|
Pharmacokinetic Parameter changes of RAG-17 in Plasma: Time to Reach Maximum Observed Concentration (Tmax) on day1, day15, day29, day60, day120, day180 and day240 in adult ALS patients after RAG-17 treatment
|
day 1, day 15, day 29, day 60, day 120, day 180 and day 240
|
Pharmacokinetic Changes of RAG-17
Time Frame: day 1, day 15, day 29, day 60, day 120, day 180 and day 240
|
Pharmacokinetic Parameter changes of RAG-17 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) on day1, day15, day29, day60, day120, day180 and day240 in adult ALS patients after RAG-17 treatment
|
day 1, day 15, day 29, day 60, day 120, day 180 and day 240
|
Pharmacokinetic Changes of RAG-17
Time Frame: day 1, day 15, day 29, day 60, day 120, day 180 and day 240
|
Pharmacokinetic Parameter changes of RAG-17 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) on day1, day15, day29, day60, day120, day180 and day240 in adult ALS patients after RAG-17 treatment
|
day 1, day 15, day 29, day 60, day 120, day 180 and day 240
|
Pharmacokinetic Changes of RAG-17
Time Frame: day 1, day 15, day 29, day 60, day 120, day 180 and day 240
|
Pharmacokinetic Parameter changes of RAG-17 in Plasma: Apparent Terminal Elimination Half-life (t1/2) on day1, day15, day29, day60, day120, day180 and day240 in adult ALS patients after RAG-17 treatment
|
day 1, day 15, day 29, day 60, day 120, day 180 and day 240
|
Mechanical ventilation
Time Frame: From day1 to day240
|
Time to invasive mechanical ventilation in adult ALS patients treated with RAG-17
|
From day1 to day240
|
Death
Time Frame: From randomization date to date of death from any cause. The assessment period is up to 8 months
|
Time of death in adult ALS patients treated with RAG-17
|
From randomization date to date of death from any cause. The assessment period is up to 8 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lung function (including forced vital capacity)
Time Frame: day 15, day 29, day 90, and day 180
|
Changes in lung function (including forced vital capacity) in adult ALS patients treated with RAG-17 on day 15, day 29, day 90, and day 180
|
day 15, day 29, day 90, and day 180
|
Severity of Fatigue (Fatigue Severity Scale - FSS)
Time Frame: day 15, day 29, day 90, and day 180
|
Fatigue Severity Scale(FSS) is a questionnaire-based scale that is used to measure the change in severity of fatigue in adult ALS patients on day 15, day 29, day 90, day 180 after RAG-17 treatment.
FSS scale is 9-items questionnaire, and each item is scored on a 7 points scale from 1 (strongly disagree) to 7 (strongly agree).
The minimum score in total is 9 points, and the maximum score possible is 63.
The higher the score means the greater fatigue severity.
|
day 15, day 29, day 90, and day 180
|
Muscle strength (Medical Research Council Scale - MRC Scale)
Time Frame: day 15, day 29, day 90, and day 180
|
Medical Research Council Scale (MRC Scale) is an assessment that is used to measure the change in muscle strength of abductor pollicis brevis muscle, abductor digiti minimi, and tibial anterior muscle in adult ALS patients treated with RAG-17 on day 15, day 29, day 90, day180.
MRC Scales ranges from grade 0 to grade 5, where grade 0 means no muscle contraction, grade 5 means muscle has full strength.
|
day 15, day 29, day 90, and day 180
|
Electromyography (EMG) measures
Time Frame: day 29, day 90, day 180
|
Electromyography(EMG) is used to determine the functional performance of muscle and the index change including compound muscle action potential(CAMP)of EMG in adult ALS patients from baseline on day 29, day 90, and day180 after RAG-17 treatment
|
day 29, day 90, day 180
|
Electromyography (EMG) Measures
Time Frame: day 29, day 90, day 180
|
Changes in EMG measures (motor unit number index) from baseline on day 29, day 90, day180 after RAG-17 treatment in adult ALS patients
|
day 29, day 90, day 180
|
Electromyography (EMG) Measures
Time Frame: day 29, day 90, day 180
|
Changes in EMG measures (motor unit size index) from baseline on day 29, day 90, day180 after RAG-17 treatment in adult ALS patients
|
day 29, day 90, day 180
|
7T magnetic resonance imaging measures
Time Frame: day 29, day 90 and day 180
|
7T magnetic resonance imaging (7T MRI) is used to measure the change in the value of body indexes in adult ALS patients treated with RAG-17 on day 29, day 90 and day180.
|
day 29, day 90 and day 180
|
Kinetic Gait Analysis-Gait Function
Time Frame: day15, day 29, day 90, and day180
|
Kinetic gait analysis is used to determine the forces created by and during movement, and measurements are collected to further determine the change in gait functions of of adult ALS patients on day 15, day 29, day 90, and day180 after RAG-17 treatment.
|
day15, day 29, day 90, and day180
|
Kinematic Gait Analysis-Gait Function
Time Frame: day15, day 29, day 90, and day180
|
Kinematic gait is studied via 3D motion analysis, Construction of the coordinates and orientation of the rigid body segments allow calculation of joint angles of the proximal and distal segment, joint angular velocity, and joint acceleration.
Measurements are collected for each joint in all three cardinal planes of motion, and it further measures the change in gait functions of of adult ALS patients on day 15, day 29, day 90, and day180 after RAG-17 treatment.
|
day15, day 29, day 90, and day180
|
Short Physical Performance Battery (SPPB) - Gait Function
Time Frame: day 15, day 29, day 90, and day 180
|
Short Physical Performance Battery (SPPB) is an objective assessment that is used to measure the change in gait functions including balance, lower extremity strength, and functional capacity of of adult ALS patients on day 15, day 29, day 90, and day 180 after RAG-17 treatment.
The test includes three different assessments: walking, sit-to-stand and balance.
A 0- to 12-point scale is used to score the sum of the three assessments with higher point values corresponding with greater levels of physical function and lower disability, and vise versa.
|
day 15, day 29, day 90, and day 180
|
Scale for the Assessment and Rating of Ataxia (SARA) - First Item: Gait
Time Frame: day 15, day 29, day 90, and day 180
|
Scale for the Assessment and Rating of Ataxia (SARA) is a performance based scale that has eight categories to assess different impairments.
The first category - gait of SARA is used to measure the change in gait function of adult ALS patients on day 15, day 29, day 90, and day 180 after RAG-17 treatment.
Gait function is scored from 0point (normal) to 8points (unable to walk).
|
day 15, day 29, day 90, and day 180
|
6-meter Walking Speed - Gait function
Time Frame: day 15, day 29, day 90, and day 180
|
6-meter walking speed is a performance test to assess walking speed over a short distance, which determine the changes in gait function of adult ALS patients on day 15, day 29, day 90, and day 180 after RAG-17 treatment.
The test will be perform in 4 trials, as the first trial is practise trial, and the average of last three trials are calculated.
|
day 15, day 29, day 90, and day 180
|
The Modified Norris Test Score - Functional ability
Time Frame: day 15, day 29, day 90, and day 180
|
The Modified Norris Test Score is a rating scale that is used to measure the change in functional ability of adult ALS patients on day 15, day 29, day 90, and day 180 after RAG-17 treatment.
This scale is composed with two parts: the Limb Norris Scale (21 items) and the Norris Bulbar Scale (13 items), each item is scored from 0 point (cannot do anything) to 3 points (normal).
|
day 15, day 29, day 90, and day 180
|
Amyotrophic Lateral Sclerosis Assessment Questionnaire -40 (ALSAQ-40) - The Quality of Life
Time Frame: day 15, day 29, day 90, and day 180
|
Amyotrophic Lateral Sclerosis Assessment Questionnaire -40 (ALSAQ-40) is a patient self-report health status PRO that is used to measure the changes in the quality of life of adult ALS patients treated with RAG-17 on day 15, day 29, day 90, and day180.
There are 40 items in ALSAQ-40 with 5 domains: physical mobility (10 items), activities of daily living and independence (10 items), eating and drinking (3 items), communication (7 items), emotional reactions (10 items), each domain has a total score of 100 points, where 0 point means the worst health condition, and 100points means the best health condition.
|
day 15, day 29, day 90, and day 180
|
The EuroQol 5 Dimension 5 Level (EQ-5D-5L)- The Quality of Life
Time Frame: day 15, day 29, day 90, and day 180
|
The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-report survey that is used to measure the changes in the quality of life of adult ALS patients treated with RAG-17 on day 15, day 29, day 90, and day180.
EQ-5D-5L contains 5 domains including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and each domain is scored on a 5-level severity from Level1(no difficulty) to Level5 (extreme difficulty).
|
day 15, day 29, day 90, and day 180
|
Hamilton Anxiety Scale (HAM-A) - The Quality of Life
Time Frame: day 15, day 29, day 90, and day 180
|
Hamilton Anxiety Scale (HAM-A) is a rating scale that is used to measure the changes in severity of anxiety of adult ALS patients treated with RAG-17 on day 15, day 29, day 90, and day180.
The scale is composed of 14 items, Each item is scored on a scale of 0 (no symptom) to 4 (severe), with a total score range of 0 to 56, where <7 means no symptom of anxiety, over 24 means mild to moderate severity, >29 means extreme severity.
|
day 15, day 29, day 90, and day 180
|
Hamilton Depression Scale (HAM-D)-The Quality of Life
Time Frame: day 15, day 29, day 90, and day 180
|
Hamilton Depression Scale (HAM-D) is a rating scale that is used to measure the changes in severity of depression of adult ALS patients treated with RAG-17 on day 15, day 29, day 90, and day180.
For the 17-item version, scores can range from 0 to 54. Scores between 0 and 6 indicate a normal person , scores between 7 and 17 indicate mild depression, scores between 18 and 24 indicate moderate depression, and scores over 24 indicate severe depression.
|
day 15, day 29, day 90, and day 180
|
King's Staging System - Clinical staging of patients
Time Frame: day 15, day 29, day 90, and day 180
|
King's staging system is used to measure the change in clinical stages of adult ALS patients on day 15, day 29, day 90, and day 180 after RAG-17 treatment.
The King's staging system consists of five disease stages, with Stage 5 being death.
Stage 4 is nutritional failure.Stages 1-3 are based upon the number of El Escorial central nervous system (CNS) regions involved in the disease, measured by weakness, wasting, spasticity, dysphagia, or dysarthria.
|
day 15, day 29, day 90, and day 180
|
The Milano-Torino (MiToS) Staging - Clinical staging of patients
Time Frame: day 15, day 29, day 90, and day 180
|
The Milano-Torino (MiToS) Staging is used to measure the change in clinical stages of adult ALS patients on day 15, day 29, day 90, and day 180 after RAG-17 treatment.
The Milano-Torino (MiToS) Staging is composed with six stages, where stage 0 is no functional impairment, stage 1 is loss of one type of function, stage 2 is loss of two type of function, stage 3 is loss of three type of function, stage 4 is loss of four type of function, and stage 5 is death.
|
day 15, day 29, day 90, and day 180
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: YiLong Wang, Beijing Tiantan Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Emery AE, Holloway S. Familial motor neuron diseases. Adv Neurol. 1982;36:139-47. No abstract available.
- Feldman EL, Goutman SA, Petri S, Mazzini L, Savelieff MG, Shaw PJ, Sobue G. Amyotrophic lateral sclerosis. Lancet. 2022 Oct 15;400(10360):1363-1380. doi: 10.1016/S0140-6736(22)01272-7. Epub 2022 Sep 15.
- Chen L, Zhang B, Chen R, Tang L, Liu R, Yang Y, Yang Y, Liu X, Ye S, Zhan S, Fan D. Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China. J Neurol Neurosurg Psychiatry. 2015 Oct;86(10):1075-81. doi: 10.1136/jnnp-2015-310471. Epub 2015 Jun 29.
- Rosenbohm A, Liu M, Nagel G, Peter RS, Cui B, Li X, Kassubek J, Rothenbacher D, Lule D, Cui L, Ludolph AC; ALS Registry Swabia Study Group. Phenotypic differences of amyotrophic lateral sclerosis (ALS) in China and Germany. J Neurol. 2018 Apr;265(4):774-782. doi: 10.1007/s00415-018-8735-9. Epub 2018 Feb 1.
- Amyotrophic Lateral Sclerosis (ALS) Fact Sheet. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/amyotrophic-lateral-sclerosis-als-fact-sheet#treatment. October 2022.
- Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, Kalra S, Katz JS, Mitsumoto H, Rosenfeld J, Shoesmith C, Strong MJ, Woolley SC; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009 Oct 13;73(15):1218-26. doi: 10.1212/WNL.0b013e3181bc0141. Erratum In: Neurology. 2009 Dec 15;73(24):2134. Neurology. 2010 Mar 2;74(9):781.
- Barrington CJ, Burruano M, Carney C, Choi J, Januska J, Lachuk L, Oskarsson B, Rodriguez C, Speicher L, Tereso G. Addressing the role of edaravone in the management of amyotrophic lateral sclerosis and gaps in care and access: expert panel recommendations. Am J Manag Care. 2021 Aug;27(12 Suppl):S231-S237. doi: 10.37765/ajmc.2021.88732.
- Chattopadhyay M, Valentine JS. Aggregation of copper-zinc superoxide dismutase in familial and sporadic ALS. Antioxid Redox Signal. 2009 Jul;11(7):1603-14. doi: 10.1089/ars.2009.2536.
- Shahrizaila N, Sobue G, Kuwabara S, Kim SH, Birks C, Fan DS, Bae JS, Hu CJ, Gourie-Devi M, Noto Y, Shibuya K, Goh KJ, Kaji R, Tsai CP, Cui L, Talman P, Henderson RD, Vucic S, Kiernan MC. Amyotrophic lateral sclerosis and motor neuron syndromes in Asia. J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):821-30. doi: 10.1136/jnnp-2015-312751. Epub 2016 Apr 19.
- Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017 Jul 13;377(2):162-172. doi: 10.1056/NEJMra1603471. No abstract available.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 22, 2023
Primary Completion (Estimated)
February 28, 2024
Study Completion (Estimated)
February 28, 2024
Study Registration Dates
First Submitted
May 7, 2023
First Submitted That Met QC Criteria
June 11, 2023
First Posted (Actual)
June 15, 2023
Study Record Updates
Last Update Posted (Actual)
June 15, 2023
Last Update Submitted That Met QC Criteria
June 11, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HX-A-2023004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gene Mutation
-
Marc Dall'Era, MDNational Cancer Institute (NCI); Janssen, LPRecruitingBRCA1 Gene Mutation | BRCA2 Gene Mutation | Prostate Carcinoma | RAD51C Gene Mutation | BRIP1 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CDK12 Gene Mutation | CHEK1 Gene Mutation | DNA Damage Response Gene Mutation | DNA Repair Gene Mutation | FANCA Gene Mutation and other conditionsUnited States
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedBRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | ATR Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CHEK1 Gene Mutation | FANCA Gene... and other conditionsUnited States, Canada
-
Pamela MunsterNational Cancer Institute (NCI)RecruitingBRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation | BRCA Mutation | Checkpoint Kinase 2 Gene MutationUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBRCA1 Gene Mutation | BRCA2 Gene Mutation | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | MLH1 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | BARD1 Gene Mutation | MSH2 Gene Mutation | MSH6... and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingBRCA1 Mutation | BRCA2 Mutation | APC Gene Mutation | MLH1 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | PTEN Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | BARD1 Gene Mutation | MSH2 Gene Mutation | MSH6 Gene Mutation | PMS2 Gene Mutation | POLD1 Gene... and other conditionsUnited States
-
Rabin Medical CenterUnknownBRCA1 Gene Mutation | BRCA2 Gene MutationIsrael
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers Squibb; Vanderbilt University; Avon Breast Health Access FundActive, not recruitingMetastatic Solid Tumor | SF3B1 Gene Mutation | Spliceosome Mutation | U2AF1 Gene Mutation | SRSF2 Gene MutationUnited States
-
BioMed Valley Discoveries, IncTerminatedAdvanced Solid Tumor | MAP2K1 Gene Mutation | BRAF Gene Mutation | MEK Mutation | BRAF Gene Alteration | MEK Alteration | MAP2K1 Gene Alteration | MAP2K2 Gene Mutation | MAP2K2 Gene AlterationUnited States
-
Mayo ClinicRecruitingCancer | Cancer Gene Mutation | PAN Gene MutationUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingBRCA1 Gene Mutation | BRCA2 Gene MutationUnited States
Clinical Trials on RAG-17
-
Ractigen Therapeutics.RecruitingNon-Muscle-Invasive Bladder Cancer (NMIBC)Australia
-
wei boUnknown
-
Ramos Mejía HospitalCompleted
-
Hannover Medical SchoolUnknown
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Secondary Acute Myeloid Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Acute Undifferentiated LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Thyroid Gland Medullary CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Mantle Cell Lymphoma | Anaplastic Large Cell Lymphoma | Recurrent Adult Hodgkin LymphomaUnited States
-
Wake Forest UniversityCompletedAtopic DermatitisUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin LymphomaUnited States
-
Sohag UniversityNot yet recruitingSystemic Lupus ErythematosusEgypt